A Multicenter, Open-label Study to Collect the Safety Information of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed CLCZ696B2319E1 Study
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 25 Sep 2024 Status changed from active, no longer recruiting to completed.
- 19 Jul 2024 Planned End Date changed from 30 Aug 2024 to 14 Aug 2024.
- 19 Jul 2024 Planned primary completion date changed from 29 Aug 2024 to 14 Aug 2024.